Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-NDUFS8 antibody [EPR11892] (ab170936)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR11892] to NDUFS8
  • Suitable for: WB, IHC-P, IP, Flow Cyt
  • Reacts with: Human

Overview

  • Product name

    Anti-NDUFS8 antibody [EPR11892]
    See all NDUFS8 primary antibodies

  • Description

    Rabbit monoclonal [EPR11892] to NDUFS8

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    Flow Cyt
    Human
    IHC-P
    Human
    IP
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human NDUFS8 aa 1-100. The exact sequence is proprietary.
    Database link: O00217

  • Positive control

    • HeLa, HepG2 and Jurkat cell lysates, Human liver tissue, Human thyroid carcinoma tissue, permeabilized Jurkat cells, immunoprecipitation pellet from HeLa cell lysate

  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-NDUFS8 antibody [EPR11892] (ab170936)
    Western blot - Anti-NDUFS8 antibody [EPR11892] (ab170936)
    All lanes : Anti-NDUFS8 antibody [EPR11892] (ab170936) at 1/1000 dilution

    Lane 1 : HeLa cell lysates
    Lane 2 : HepG2 cell lysates
    Lane 3 : Jurkat cell lysates

    Lysates/proteins at 10 µg per lane.

    Predicted band size: 23 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NDUFS8 antibody [EPR11892] (ab170936)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NDUFS8 antibody [EPR11892] (ab170936)

    Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling NDUFS8 with ab170936 at 1/250 dilution.

    Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NDUFS8 antibody [EPR11892] (ab170936)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NDUFS8 antibody [EPR11892] (ab170936)

    Immunohistochemical analysis of paraffin-embedded Human thyroid carcinoma tissue labeling NDUFS8 with ab170936 at 1/250 dilution.

    Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

  • Flow Cytometry - Anti-NDUFS8 antibody [EPR11892] (ab170936)
    Flow Cytometry - Anti-NDUFS8 antibody [EPR11892] (ab170936)

    Flow cytometric analysis of permeabilized Jurkat cells using ab170936 (red) at 1/10 dilution or a rabbit IgG (negative) (green).

  • Immunoprecipitation - Anti-NDUFS8 antibody [EPR11892] (ab170936)
    Immunoprecipitation - Anti-NDUFS8 antibody [EPR11892] (ab170936)

    Western blot analysis on immunoprecipitation pellet from (1) HeLa cell lysate or (2) 1X PBS (negative control) using ab170936 at 1/10 dilution and HRP-conjugated anti-rabbit IgG preferentially detecting the non-reduced form of rabbit IgG.

  • Anti-NDUFS8 antibody [EPR11892] (ab170936)
    Anti-NDUFS8 antibody [EPR11892] (ab170936)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-NDUFS8 antibody [EPR11892] (ab170936)

Clear all

Recently viewed products

© 2021 Astana Biomed Group LLP. All rights reserved.